Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study

By sjmartinez • January 18, 2024

Aggarwal R, Schessl J, Charles-Schoeman C, Bata-Csörgő Z, Dimachkie MM, Griger Z, Moiseev S, Oddis CV, Schiopu E, Vencovský J, Beckmann I, Clodi E, Levine T; ProDERM investigators. Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study. Arthritis Res Ther. 2024 Jan 17;26(1):27. doi: 10.1186/s13075-023-03232-2. PMID: 38233885.

Tags: Dermatomyositis, Intravenous immunoglobulin, Myositis, Publications, Rheumatology, safety, Tolerability

Evaluation of the Reliability and Validity of the Retirement Knowledge Scale (RKS)

Blanco LR, Hays RD. Evaluation of the Reliability and Validity of the Retirement Knowledge Scale (RKS). J Retire. 2024 Fall;12(2):76-94. doi: 10.3905/jor.2024.1.164. Epub 2024 Oct[...]

Phosphate Binder Impairs Levothyroxine Absorption in a Hypothyroid Patient With End-Stage Renal Disease

Ko M, Barai R, Brent G. Phosphate Binder Impairs Levothyroxine Absorption in a Hypothyroid Patient With End-Stage Renal Disease. Cureus. 2024 Oct 15;16(10):e71551. doi: 10.7759/cureus.71551.[...]

Patient-Identified Treatment Goals for Psoriatic Disease: Results From a US Patient Survey

Armstrong A, Levit NA, Schneider B, Seiden R, Shi L, Kaplan B, Wu JJ. Patient-Identified Treatment Goals for Psoriatic Disease: Results From a US Patient[...]